• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    WDSrx Expands Warehouse Network

    Piramal Inks Clinical Supply Deal with Theratechnologies

    Recipharm Signs Manufacturing Deal with Enzymatica

    CDMO Northway Biotech Expands in U.S.

    Global Biosciences Co. Selects ValGenesis VLMS
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    WDSrx Expands Warehouse Network

    Piramal Inks Clinical Supply Deal with Theratechnologies

    Recipharm Signs Manufacturing Deal with Enzymatica

    CDMO Northway Biotech Expands in U.S.

    Lonza to Exit Pharma Softgels and Liquid-Filled Hard Capsules
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    WDSrx Expands Warehouse Network

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Improving Product Profitability

    CDMO Northway Biotech Expands in U.S.

    Global Biosciences Co. Selects ValGenesis VLMS

    Nexelis Acquires GSK Vax Lab in Marburg

    The Future of Clinical Trials Series: Part I
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

    CDMO Cognate BioServices Teams Up with L7 Informatics
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Adare Pharma Solutions

    PCI Pharma Services

    Emergent BioSolutions

    Cytovance Biologics
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Emergent BioSolutions

    Baxter BioPharma Solutions

    Aphena Pharma Solutions

    Cytovance Biologics

    Flow Sciences
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Leveraging Next-Gen FSP Models to Better Manage Post-approval Regulatory Workloads

    One-team Model forges an outsourcing partnership to deliver efficient global regulatory lifecycle management

    Leveraging Next-Gen FSP Models to Better Manage Post-approval Regulatory Workloads
    Leveraging Next-Gen FSP Models to Better Manage Post-approval Regulatory Workloads
    Related CONTENT
    • The Slow – But Desperately Needed – Evolution of Oncology Clinical Development Designs
    • Parexel Appoints Chief Patient Officer
    • Financial Report: PPD
    • Moderna Completes Enrollment in Phase III COVID-19 Vax Study
    • PPD to Open Multipurpose Clinical Research Lab in Suzhou
    Elizabeth Madichie, Alistair Davidson, Denise Moody and Vincenzo Cannizzaro, PPD05.09.17
    Increasing workloads, decreasing resources. How can biopharma companies cope with the escalating demands of regulatory lifecycle management? The regulatory effort needed to maintain product licenses is growing dramatically in terms of both volume and regulatory requirements, pushing sponsors’ resources to the limit. A new outsourcing model built on a closely managed partnership promises a solution.

    Regulatory lifecycle management includes ongoing submissions to address labeling changes, chemistry, manufacturing and control (CMC) updates, Periodic Safety Update Reports/Periodic Benefit-Risk Evaluation Reports (PSUR/PBRER) and other safety variations, administrative changes and renewals to ensure regulatory compliance in every country where a product is registered, as well as new registrations in emerging markets for established products. For one major biopharma company, the maintenance of roughly 5,000 product licenses in 150 markets has generated more than 25,000 submissions over the last four years. The top 30 pharma companies are making thousands of regulatory submissions globally on an annual basis; more than 80 percent of these are related to post-approval activities.

    Escalation of time-consuming regulatory workload puts greater pressure on biopharma staffing resources, which are already strained by ever-tighter development timelines. For example:
    • In the pre-approval arena, resources are stretched by rising development costs and the imperative to reduce time to market. Greater support is needed to manage the complexity of global development pathways, changing licensing procedures and the engagement of multiple regulatory agencies.
    • In the post-approval arena, the volume of lifecycle regulatory work is increased by line extensions, new clinical indications, registration of existing products in emerging markets and patent-life management strategies. Greater focus on post-approval drug safety and quality is driving a worldwide escalation in compliance demands and growing regulatory requirements. To cite one example, the U.S. Food and Drug Administration (FDA) expects to start collecting quality metrics data from biopharmaceutical manufacturers in January 2018 to help assess how well a sponsor can measure key elements of a quality drug production operation. 
    Outsourcing strategies that can reduce the in-house burden of managing product licenses globally across large portfolios allow sponsors to focus a greater proportion of their regulatory resources on pre-approval product development. However, outsourcing critical post-approval regulatory compliance work to a contract service provider demands a high level of confidence and trust in both the provider and the process.

    The outsourcing strategy described here, called the “One-team Model,” is a closely integrated and managed partnership co-developed by a biopharma company and its provider—in this case PPD, a global CRO—to manage all post-approval regulatory activities across a large global product portfolio. The One-team Model expands the functional service partnership (FSP) model to increase efficiencies with constant operational re-engineering throughout the lifetime of the partnership. It standardizes high-quality lifecycle strategies and associated submission packages by fully aligning goals and processes between the respective regulatory teams.

    Innovating the FSP model
    Traditional FSP models implement broad, portfolio-based functions, such as data management or medical writing, in structures aimed at streamlining operations. An FSP bundles and conducts repetitive, high-volume tasks across multiple projects.

    The classic FSP “hub-and-spoke” model—which centralizes core operations (the hub) and distributes outputs to multiple, geographically dispersed users (the spokes)—has succeeded in increasing efficiencies in other areas of product development, including biometrics and medical writing. What biopharma companies need to make this approach deliver the same benefits for regulatory lifecycle management is an outsourcing model that combines operational efficiencies with high levels of local regulatory expertise.

    This partnership has created a solution by adopting certain features of this strategy and advancing it further by embedding strategic regulatory and product knowledge expertise within its delivery. In the One-team Model, PPD leverages its global regulatory knowledge and expertise through the provision of core regulatory submission leads (RSL) and specialists who partner at a strategic level internally with the sponsor and who direct the highly efficient centralized core regulatory operations team.

    The regulatory centers provide core functions—such as planning, document authoring, data compilation, publishing and direct submission (where applicable)—in locations that offer lower cost together with high-quality, experienced regulatory staff. These centers are located in Latin America (Mexico), Asia (India and the Philippines), and Eastern Europe (Bulgaria).

    The specialized centers generate submission packages to support product licenses worldwide. They provide the resources and dedicated technologies needed to manage large-volume document preparation workloads and deliver ready-to-submit documents to the sponsor’s country-based regulatory experts. Planning and preparation of submissions are conducted under the guidance of regulatory experts experienced in post-approval submission requirements for global jurisdictions.

    To provide the country-specific requirements and maintain the all-important relationships with local health authorities, the partnership combines the sponsor’s local, in-country regulatory managers, and the provider’s local offices and regulatory intelligence database.

    Road map to the one-team model
    The One-team Model was designed to manage an outsourcing project of unprecedented size and scope. Teams comprised of regulatory experts from both companies and change management experts from the provider crafted a tightly integrated partnership that defined strategy, planning and operational roles and responsibilities, set standards for quality submissions, and improved processes and procedures for maximum time and cost efficiencies.

    The goal was to design a customized partnership to support all post-approval regulatory work and implement a culture of continuous improvement based on documented “road maps” to define and direct the working partnership in five areas:
    • Performance oversight
    • Processes, tasks, planning, roles and responsibilities
    • QA, QC, business continuity
    • Contract and budget, scope, resourcing
    • IT systems, reports, queries
    The partnership was structured initially to maintain regulatory compliance for more than 5,000 product licenses encompassing 49 molecules (47 products) across the regulatory jurisdictions of all countries, with the exception of China and Japan, although these would be added later.
    In addition to freeing the sponsor’s regulatory staff to focus on pre-approval work, the integrated partnership would create a platform to:
    • Generate consistent, high-quality submissions across global markets
    • Track, report and deploy new regulation and evolving regulation in emerging markets
    • Implement key performance indicators (KPI) and metrics to monitor partnership performance, while using metrics to inform continuous improvement activities
    • Act as a catalyst for change based on reviewing current practices, and recommending and implementing new processes, procedures and behaviors
    Trust was key to implementing the envisioned model effectively. Forging a single team from two different corporate cultures, technical platforms and operational processes required a high degree of open communication, emotional intelligence and interpersonal understanding.

    The framework: Five steps in the one-team model
    The first challenge was to decide which regulatory competencies would remain in-house with the sponsor and which would be outsourced. The partners began by establishing a framework that delineated the major regulatory submissions and post-approval activities, together with the groups that would be responsible for conducting them and the sequence in which they occurred. The framework designated five major fields of activity and assigned responsibilities within each, as well as the core strategic competencies for the partnership manager (PM).

    Handover Trigger. The sponsor’s marketed product lead (MPL) informs PPD that a regulatory lifecycle action is required. The sponsor’s MPL executes the handover, officially assigning the work to the PPD RSL and provides the key corporate target milestones. Planning for pre-defined activities like license renewals can be triggered directly by the RSL, who has access to the data that drives the efforts. 

    Strategy, Resourcing and Overarching Planning. The RSL defines the submission strategy and the detailed tasks, milestones and timelines to achieve on-time submissions. The plan for submission includes input from the specialists who help ensure that the plan is built upon the latest regulatory requirements for relevant countries. In the One-team Model, the RSLs are responsible for product expertise, retention of product knowledge and owning the strategy for the product’s entire life cycle.

    Supporting Documents. The sponsor’s relevant functional teams provide the supporting documents and data for the submissions.

    Submission Planning, Compilation, Publishing and Dispatch. Once the overarching submission plan is confirmed by the MPL and RSL, this is executed by the specialists in the regulatory centers. Working together with the sponsor’s functional teams—for example, the medical or CMC specialists—they execute the plan to deliver the submission package according to the agreed timelines.

    The specialists prepare submission packages using their knowledge of local requirements and that of the sponsor’s functional teams. When new local requirements are identified, they are added to PPD’s regulatory knowledge database, which maintains and reports on global regulatory intelligence, including clinical trial requirements and marketing authorizations.

    The PPD RSL oversees the timely execution of the submission plan by its specialists. Before dispatching the package to the sponsor’s in-country managers, the RSL also conducts quality control prior to final publication of the submission documents/dossier.

    Local Country Submission Interface. The sponsor’s local country affiliate serves as the interface between the package preparation and its submission to the local regulatory agency. The sponsor’s country affiliates finalize the global package in line with local requirements—such as providing translations—and then submit it to the local health authority according to the agreed strategy and timelines. For some countries/regions that utilize electronic submissions (e.g., those using the EU eSubmission Gateway and the FDA’s Electronic Submissions Gateway), PPD specialists submit the package directly to the authorities.

    Managing risk
    Initial and ongoing risk assessment is considered essential to the successful functioning of the partnership.

    Initial Risk Assessment. Five general categories of potential risk were identified at the start of the partnership: technology; cultural differences; governance; ownership of roles and responsibilities; and processes. Specific work streams were established to examine the frequency, probability and impact of the major risks in each category, and to agree on mitigation approaches. These work streams proved highly effective in reducing the impact of major risks and ensuring that mitigations were conducted in a timely manner, without impacting the delivery of milestones.

    Ongoing Risk Assessment. It was agreed that ongoing risk assessment would be conducted at both the product and process levels. Designated staff assess and prioritize risks twice a year for regulatory lifecycle management processes. If critical risks are identified, mitigation actions are determined, agreed upon and implemented.

    At the product level—that is, for each regulatory submission—risk assessment and mitigation is conducted by the RSLs to manage risks related to the specific submissions and deliverables, such as those associated with regulatory timelines and commitments.

    To date, ongoing risk assessment has proved highly effective in ensuring that processes are fit for purpose and aligned with the needs of the partnership and the ever-changing regulatory environment.

    Measuring performance: Key metrics
    Successful management of the integrated steps across the partnership demands close monitoring of overall performance at the partnership level, as well as performance of the two organizations.

    Overall Partnership KPIs/KQIs. Objectives are reflected in the KPIs and key quality indicators (KQI). KPIs and KQIs were established to ensure, for example, that dossiers are submitted according to mandatory regulatory agency deadlines for all types of regulatory deliverables, and that there are no critical findings in any audit carried out via the partnership.

    PPD team KPIs/KQIs: These metrics reflect the work of the PPD team members, for example, those pertaining to timely planning in the partnership’s regulatory information management system (RIMS). KPIs and KQIs ensure that all RIMS sequences associated with a submission are created within the established timeline and that all regulatory packages provided to country regulatory agencies contain the required (published) submission documents.

    Sponsor KPIs/KQIs. These metrics apply to the work of the sponsor’s team, such as metrics pertaining to the handoff trigger, which aim at ensuring entry into RIMS within the agreed timetable.

    Managing change
    The partnership recognized that a smooth transition to this new operating model would depend on effective change management. The sponsor’s regulatory staff would be learning and implementing new approaches to conduct post-approval work, which would require that they trust PPD’s processes and staff as the outsourcing partner took on its designated responsibilities.

    The change management transition team was comprised of key stakeholders from the two entities. With both partners designing the model, the decision-making process and benefits were clear to both organizations. Key stakeholders then became advocates for the partnership within their own organizations. Regular communication updates were shared with all stakeholders; timelines and milestone metrics were communicated to all.

    Co-development of responsibilities, timelines and quality standards became an effective catalyst for change with the partner organizations. For example, the sponsor adopted the KPIs for internal use and created a recognition and reward incentive program to enhance employee acceptance of the new model.

    The one-team model in action
    Earlier in the article, we spoke of the need to develop trust within the partnership. It has taken time to build mutual respect and confidence across the co-designed model. Both companies would agree that the creation of a harmonious partnership culture, now capable of working closely and effectively, has been as important to achieving the partnership’s benefits as the new model’s structuring of activities.

    The partnership has accomplished its primary goal of managing post-approval licenses for the sponsor’s global product portfolio in full compliance with good regulatory practices. This highly efficient performance serves to increase the return on investment of existing mature licenses by new submissions and approvals in emerging markets. Reduction of the sponsor’s post-approval regulatory workload has enabled in-house staff to focus on pre-approval work. In addition to the efficiencies provided by the centralized management of this huge regulatory workload, the model offers the flexibility to respond quickly to changing regulatory requirements and the sponsor’s corporate policies.

    An example of this responsive flexibility—an attribute highly sought after by global companies—is demonstrated by the response required by the team following the implementation in 2016 of the sponsor’s new standard operating procedure (SOP) aimed at the creation and updating of referenced product information and its global implementation. The new SOP requires that each safety variation be dispatched globally within 180 days of signal validation.

    PPD managed a multiplicity of updates in the company’s core data sheets (CCDS) for five products, all having the same active pharmaceutical ingredient. Within the reduced SOP-mandated timeline, the company created and dispatched more than 700 submissions generated by the CCDS update by quickly re-engineering resources and concomitant deliverables.

    Future applications
    The benefits achieved by the One-team Model point to the value of integrated sponsor-provider partnerships. The model offers both efficiency and flexibility to better manage regulatory workflows, and expand capacity for post-approval license maintenance for new products in new markets and emerging countries, while releasing valuable in-house resources to focus on accelerating new products to market. In addition, the model provides drivers for an organization’s own change by leveraging ongoing experience from the provider and expanding the platform to conduct new tasks and services.

    In this joint effort, for example, the partnership was redesigned after the first year of operation to optimize processes, tools and structure. This redesign established a pathway for more upstream strategic input and allowed for future geographical expansion. Changes in roles and responsibilities had important impacts on operational efficiencies. Before the partnership, the sponsor operated through marketed product leads and emerging marketed product leads (EMPL). These roles have since been combined into one MPL to partner more efficiently with PPD’s RSL. The role of the PPD PM has now been expanded to manage across the partnership rather than just the company’s elements. This change eliminated duplication and empowered the PM to liaise with a broader group of the sponsor’s stakeholders.

    Integrated partnerships will continue to drive alignments of sponsors and outsource providers in more flexible, efficient configurations. The future of the One-team Model is now taking shape in a number of new PPD-sponsor partnerships marked by greater provider-sponsor integration and more cross-functional services. PPD also has expanded the One-team Model to incorporate pharmacovigilance, medical writing and preclinical/CMC regulatory work. In addition, the one-team platform facilitates the evolution to outsource local in-country regulatory activities—traditionally conducted in-house, which further enables the most effective and efficient delivery for full lifecycle activities.

    The success of the One-team Model is a compelling argument for the wider application of this outsourcing approach as advancing technologies and increasing cost drivers heighten demand for outsourcing partnership solutions. 

    References
    1. Figure based on PPD lifecycle regulatory services provided to a top-10 biopharma company
    2. FDA; CDER SBIL Chronicles, Nov 30, 2016. FDA’s Quality Metrics Reporting Program: Submission to Quality Metrics Data.  https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/UCM531066.pdf
    Related Searches
    • production
    • pharma companies
    • data management
    • latin america
    Suggested For You
    The Slow – But Desperately Needed – Evolution of Oncology Clinical Development Designs The Slow – But Desperately Needed – Evolution of Oncology Clinical Development Designs
    Parexel Appoints Chief Patient Officer Parexel Appoints Chief Patient Officer
    Financial Report: PPD Financial Report: PPD
    Moderna Completes Enrollment in Phase III COVID-19 Vax Study Moderna Completes Enrollment in Phase III COVID-19 Vax Study
    PPD to Open Multipurpose Clinical Research Lab in Suzhou PPD to Open Multipurpose Clinical Research Lab in Suzhou
    Gaylord Chemical Company Gaylord Chemical Company
    SGS Expands Stability Capacity at Mississauga Lab SGS Expands Stability Capacity at Mississauga Lab
    Breaking New Ground: How Industry Collaboration is Transforming Clinical Research Breaking New Ground: How Industry Collaboration is Transforming Clinical Research
    Sharp Serialisation Update Sharp Serialisation Update
    Emergent BioSolutions Signs $53 Million BARDA Contract Emergent BioSolutions Signs $53 Million BARDA Contract
    Establishments, Identifications, Submissions and Beyond Establishments, Identifications, Submissions and Beyond
    Paratek Opens New Office in King of Prussia Paratek Opens New Office in King of Prussia
    Recipharm Extends Partnership with Sato Pharmaceutical Recipharm Extends Partnership with Sato Pharmaceutical
    Adents, Microsoft Present Serialization Solution Adents, Microsoft Present Serialization Solution
    Pfizer CentreOne Expands Service Portfolio Pfizer CentreOne Expands Service Portfolio

    Related Features

    • Excipients
      Bye-Bye China?

      Bye-Bye China?

      Instead of closing its doors on China, Western pharma industry needs to take a balanced approach and perform proper due diligence based on objective criteria.
      Michele Jermini and Enrico Polastro 11.17.20

    • Clinical Trials | Information Technology | R&D
      Decentralized Trials Fuel AI Revolution in Clinical Research

      Decentralized Trials Fuel AI Revolution in Clinical Research

      The life sciences industry is giving clinical a full makeover, dramatically improving how new therapeutics are developed.
      Nick Moss, Vice President of Analytics and Machine Learning, Medable 11.17.20

    • Drug Delivery | Injectables
      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Bringing together self-medication with auto-injectors and sustainable secondary packaging.
      Matthias Heinrichs, Head of Product Management and Project Engineering, Syntegon Technology 11.17.20


    • The Single-Use Mixing Landscape: Evaluating Your Options

      The Single-Use Mixing Landscape: Evaluating Your Options

      Adoption of single-use technologies has increased markedly in recent years and will continue to grow.
      Mark A. Sitcoske, Founder & CEO, High Purity New England 11.17.20

    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      Lonza’s Director of Commercial Development, Sean Diver, was recently named President of DCAT.
      Tim Wright, Editor, Contract Pharma 11.17.20

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20


    • Injectables
      Catering for the Complex

      Catering for the Complex

      The rapidly changing landscape of pharmaceutical packaging.
      Marcelo Cruz, Director Business Development and Marketing, Tjoapack 11.17.20

    • Cold Chain Management | Supply Chain
      Cold Chain Trends

      Cold Chain Trends

      There is a growing need for convenience through Direct-to-Patient and Direct-from-Patient services in clinical trials.
      Vince Paolizzi, Director of NanoCool Sales, Pelican BioThermal 11.17.20

    • Biologics, Proteins, Vaccines | Inspections | Supply Chain
      Inspecting the Unexpected

      Inspecting the Unexpected

      Preparing quality control processes for COVID-19 vaccine candidates.
      Dr. Andrea Sardella and Raffaele Pace, Stevanato Group 11.17.20


    • Scale-up/Technology Transfer
      Ensuring Quality During the Transfer and Scale Up of Rx Drugs

      Ensuring Quality During the Transfer and Scale Up of Rx Drugs

      Defining the key parameters and considerations for a successful technology transfer.
      Tom Chang, President, Bora Pharmaceutical Laboratory Co. Ltd. 11.17.20

    • Scale-up/Technology Transfer
      Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up

      Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up

      Identifying, assessing and mitigating threats at every stage of the development pipeline.
      Joe Willmot, Application Leader, H.E.L Group 11.17.20

    • Clinical Trials | Information Technology
      The Role of Electronic Monitoring in Maintaining Medication Adherence

      The Role of Electronic Monitoring in Maintaining Medication Adherence

      Digital solutions offer hope to get patients to take their medications properly.
      Bernard Vrijens, Scientific Lead, AARDEX Group 10.14.20


    • APIs
      Understanding the Importance of Crystallization Processes

      Understanding the Importance of Crystallization Processes

      Crystallization is a crucial aspect of a molecule’s development and can be used to avoid unnecessary cost, risk and development delays.
      Dr. Craig Callahan, Project Scientist, Cambrex Edinburgh 10.14.20

    • Capsules | Solid Dosage/Creams/Ointments
      Capsule Technology Trends

      Capsule Technology Trends

      A look at the capsule market with a particular focus on the factors driving increased demand in non-gelatin-based formulations.
      Julien Lamps, Product Manager, Lonza 10.14.20

    • Aseptic Processing | Fill/Finish
      A Holistic Cleanroom Concept: Higher Quality and Greater Flexibility

      A Holistic Cleanroom Concept: Higher Quality and Greater Flexibility

      Overcoming today’s aseptic fill-and-finish process challenges.
      Ute Schleyer, Project Manager, Site & Plant Development, Vetter 10.14.20

    Trending
    • The Future Of Clinical Trials Series: Part I
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • Lonza To Exit Pharma Softgels And Liquid-Filled Hard Capsules
    • Nexelis Acquires GSK Vax Lab In Marburg
    • CDMO Northway Biotech Expands In U.S.
    Breaking News
    • WDSrx Expands Warehouse Network
    • Piramal Inks Clinical Supply Deal with Theratechnologies
    • Recipharm Signs Manufacturing Deal with Enzymatica
    • CDMO Northway Biotech Expands in U.S.
    • Global Biosciences Co. Selects ValGenesis VLMS
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    NIH Study Compares Low-Fat, Plant-based to Low-Carb, Animal-Based Diet
    Gadot Positions Mineral Line for Vegan Market
    Nutritfy India to Launch Global Broadcast Channel Covering Nutrition
    Coatings World

    Latest Breaking News From Coatings World

    IGL Coatings Launches Graphene Reinforced Dual System Ceramic Coating
    Miller Paint Declares Simple Serenity its 2021 Color of the Year
    TAUBMANS Paint by PPG Releases ‘Chromatic Joy’ Palettes
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    TPI Partners with Zeiss
    PPE Moves into New Manufacturing Facility
    Neurent Medical Closes $25 Million Series B Financing
    Contract Pharma

    Latest Breaking News From Contract Pharma

    WDSrx Expands Warehouse Network
    Piramal Inks Clinical Supply Deal with Theratechnologies
    Recipharm Signs Manufacturing Deal with Enzymatica
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Lageen Tubes Launches Mono-Material PE Tube Solutions
    Jason Jones Loses Battle with Covid-19
    Weleda Celebrates 100 Years By 'Opening' Its Gardens
    Happi

    Latest Breaking News From Happi

    NY's 1,4-Dioxane Law May Impact Concentrated Cleaners
    Sabinsa's Top Scientist Addresses US FDA
    Ipsy Adds New Personal Care Brand
    Ink World

    Latest Breaking News From Ink World

    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    THIMM Group Installs 1st Koenig & Bauer CorruFLEX
    Cowan Graphics Adds Fujifilm Inca OnsetX3 HS
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Lemu Group engineers mask-making machine
    Niagara Label upgrades with Nilpeter flexo press
    Soma partners with Moore & Moore in US
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Lemu Group Engineers Mask-Making Machine
    Armbrust American Adds Meltblown Manufacturing
    P&G Reports 8% Sales Increase
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Siemens Healthineers’ DR Systems Cleared by FDA
    Former Medtronic Exec Appointed Zimmer Biomet's Chief Transformation Officer
    SeaSpine Launches Regatta Lateral Plates
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Roadsimple Modernizes Warehouse Ops with Zebra Technologies
    Graphene Flagship Launches Redesigned Website

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login